TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Pivotal, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Milnacipran for the Treatment of Fibromyalgia
Brief Summary: Antidepressants of all varieties represent a common form of therapy for many chronic states including fibromyalgia. The majority of antidepressants increase the levels of serotonin or norepinephrine in the central nervous system. Milnacipran is a dual norepinephrine and serotonin reuptake inhibitor and may be effective in the treatment of fibromyalgia.


Options:
A: Arm Label: Minalcipran 100 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Arm Label: Minalcipran 150 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Arm Label: Minalcipran 200 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Intervention Type: DRUG; Name: milnacipran; Assigned to Arm(s): Minalcipran 100 mg, Minalcipran 150 mg, Minalcipran 200 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Minalcipran 100 mg, Minalcipran 150 mg, Minalcipran 200 mg
B: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: milnacipran hydrochloride; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Pivotal, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Milnacipran for the Treatment of Fibromyalgia
Brief Summary: Antidepressants of all varieties represent a common form of therapy for many chronic states including fibromyalgia. The majority of antidepressants increase the levels of serotonin or norepinephrine in the central nervous system. Milnacipran is a dual norepinephrine and serotonin reuptake inhibitor and may be effective in the treatment of fibromyalgia.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): D
B: Arm Label: Milnacipran; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Milnacipran, Drug: Placebo | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): Milnacipran, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Milnacipran, Placebo
C: Arm Label: CBT and milnacipran; Type: EXPERIMENTAL; Interventions: Other: CBT and milnacipran | Arm Label: CBT and placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: CBT with a placebo | Arm Label: Educational with milnacipran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Educational with milnacipran | Intervention Type: OTHER; Name: CBT and milnacipran; Assigned to Arm(s): CBT and milnacipran | Intervention Type: BEHAVIORAL; Name: CBT with a placebo; Assigned to Arm(s): CBT and placebo | Intervention Type: DRUG; Name: Educational with milnacipran; Assigned to Arm(s): Educational with milnacipran
D: Intervention Type: DRUG; Name: milnacipran hydrochloride; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Pivotal, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Milnacipran for the Treatment of Fibromyalgia
Brief Summary: Antidepressants of all varieties represent a common form of therapy for many chronic states including fibromyalgia. The majority of antidepressants increase the levels of serotonin or norepinephrine in the central nervous system. Milnacipran is a dual norepinephrine and serotonin reuptake inhibitor and may be effective in the treatment of fibromyalgia.


Options:
A: Arm Label: Minalcipran 100 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Arm Label: Minalcipran 150 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Arm Label: Minalcipran 200 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Intervention Type: DRUG; Name: milnacipran; Assigned to Arm(s): Minalcipran 100 mg, Minalcipran 150 mg, Minalcipran 200 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Minalcipran 100 mg, Minalcipran 150 mg, Minalcipran 200 mg
B: Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 4
D: Intervention Type: DRUG; Name: milnacipran hydrochloride; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I Study to Evaluate the Safety and Immunogenicity of ALVAC-HIV vCP1521 in Infants Born to HIV-1 Infected Women in Uganda
Brief Summary: The purpose of this study is to test the safety of and immune response to an HIV-1 vaccine, ALVAC-HIV vCP1521, given to infants born to HIV-1 infected mothers in Uganda.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Biological: GenHevac B Pasteur | Arm Label: B; Type: EXPERIMENTAL; Interventions: Biological: GenHevac B Pasteur | Arm Label: C; Type: EXPERIMENTAL; Interventions: Biological: GenHevac B Pasteur | Intervention Type: BIOLOGICAL; Name: GenHevac B Pasteur; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: GenHevac B Pasteur; Assigned to Arm(s): B | Intervention Type: BIOLOGICAL; Name: GenHevac B Pasteur; Assigned to Arm(s): C
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Recombivax | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: Twinrix | Intervention Type: BIOLOGICAL; Name: Recombivax; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Twinrix; Assigned to Arm(s): 2
C: Intervention Type: BIOLOGICAL; Name: Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Measles-Mumps-Rubella Vaccine (Live); Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Pneumococcal Vaccine, Polyvalent (23-valent); Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Pneumococcal Conjugate Vaccine, Heptavalent; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Hepatitis B Vaccine (Recombinant); Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: ALVAC-HIV vCP1521 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: ALVAC HIV-1 vCP1521 | Intervention Type: BIOLOGICAL; Name: ALVAC-HIV vCP1521; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: ALVAC HIV-1 vCP1521; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
Brief Summary: The purpose of this study is to test whether SU011248 has activity and is safe compared to interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC).


Options:
A: Arm Label: Cohort A: MSI Positive Colorectal Cancer; Type: EXPERIMENTAL; Interventions: Drug: MK-3475 | Arm Label: Cohort B: MSI Negative Colorectal Cancer; Type: EXPERIMENTAL; Interventions: Drug: MK-3475 | Arm Label: Cohort C: MSI Positive Non-Colorectal Cancer; Type: EXPERIMENTAL; Interventions: Drug: MK-3475 | Intervention Type: DRUG; Name: MK-3475; Assigned to Arm(s): Cohort A: MSI Positive Colorectal Cancer, Cohort B: MSI Negative Colorectal Cancer, Cohort C: MSI Positive Non-Colorectal Cancer
B: Arm Label: Arm 1: nivolumab - 0.3 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: nivolumab | Arm Label: Arm 2: nivolumab - 2.0 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: nivolumab | Arm Label: Arm 3: nivolumab - 10.0 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: nivolumab | Intervention Type: BIOLOGICAL; Name: nivolumab; Assigned to Arm(s): Arm 1: nivolumab - 0.3 mg/kg | Intervention Type: BIOLOGICAL; Name: nivolumab; Assigned to Arm(s): Arm 2: nivolumab - 2.0 mg/kg | Intervention Type: BIOLOGICAL; Name: nivolumab; Assigned to Arm(s): Arm 3: nivolumab - 10.0 mg/kg
C: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon-alfa | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SU011248 | Intervention Type: DRUG; Name: Interferon-alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: SU011248; Assigned to Arm(s): 1
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Temsirolimus | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Interferon-Alfa 9MU | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Interferon-Alfa 9MU; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
Brief Summary: The purpose of this study is to test whether SU011248 has activity and is safe compared to interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC).


Options:
A: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Sorafenib, Drug: AMG 386 placebo IV | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Sorafenib | Arm Label: Arm C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib, Drug: AMG 386 placebo IV | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: AMG 386 placebo IV; Assigned to Arm(s): Arm A, Arm C
B: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon-alfa | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SU011248 | Intervention Type: DRUG; Name: Interferon-alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: SU011248; Assigned to Arm(s): 1
C: Arm Label: Avelumab in combination with axitinib; Type: EXPERIMENTAL; Interventions: Drug: Avelumab (MSB0010718C), Drug: Axitinib (AG-013736) | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Avelumab (MSB0010718C); Assigned to Arm(s): Avelumab in combination with axitinib | Intervention Type: DRUG; Name: Axitinib (AG-013736); Assigned to Arm(s): Avelumab in combination with axitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
D: Arm Label: everolimus 1L/sunitinib 2L; Type: EXPERIMENTAL; Interventions: Drug: everolimus, Drug: sunitinib | Arm Label: sunitinib 1L/everolimus 2L; Type: ACTIVE_COMPARATOR; Interventions: Drug: everolimus, Drug: sunitinib | Intervention Type: DRUG; Name: everolimus; Assigned to Arm(s): everolimus 1L/sunitinib 2L, sunitinib 1L/everolimus 2L | Intervention Type: DRUG; Name: sunitinib; Assigned to Arm(s): everolimus 1L/sunitinib 2L, sunitinib 1L/everolimus 2L

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
Brief Summary: The purpose of this study is to test whether SU011248 has activity and is safe compared to interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC).


Options:
A: Arm Label: Sorafenib (Nexavar, BAY43-9006); Type: EXPERIMENTAL; Interventions: Drug: Sorafenib (Nexavar, BAY43-9006) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sorafenib (Nexavar, BAY43-9006); Assigned to Arm(s): Sorafenib (Nexavar, BAY43-9006) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon-alfa | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SU011248 | Intervention Type: DRUG; Name: Interferon-alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: SU011248; Assigned to Arm(s): 1
C: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon-alfa | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SU011248 | Intervention Type: DRUG; Name: Interferon-alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: SU011248; Assigned to Arm(s): 1
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon Alfa | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: CCI-779 | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Interferon Alfa and CCI-779 | Intervention Type: DRUG; Name: Interferon Alfa; Assigned to Arm(s): A | Intervention Type: DRUG; Name: CCI-779; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Interferon Alfa and CCI-779; Assigned to Arm(s): C

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Study of Fludarabine + Rituximab Induction Followed by Alemtuzumab (Campath-1H, NSC #715969, IND #10864) Administered Subcutaneously as Consolidation in Untreated Patients With B-Cell Chronic Lymphocytic Leukemia
Brief Summary: This phase II trial is studying how well giving fludarabine together with rituximab followed by alemtuzumab works in treating patients with chronic lymphocytic leukemia. Monoclonal antibodies, such as rituximab and alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others can find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving fludarabine together with rituximab followed by alemtuzumab may kill more cancer cells.


Options:
A: Intervention Type: DRUG; Name: HuMax-CD20; Assigned to Arm(s): N/A
B: Arm Label: Idelalisib + rituximab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Idelalisib, Drug: Rituximab | Arm Label: Placebo + rituximab; Type: PLACEBO_COMPARATOR; Interventions: Drug: Rituximab, Drug: Placebo to match idelalisib | Intervention Type: DRUG; Name: Idelalisib; Assigned to Arm(s): Idelalisib + rituximab | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Idelalisib + rituximab, Placebo + rituximab | Intervention Type: DRUG; Name: Placebo to match idelalisib; Assigned to Arm(s): Placebo + rituximab
C: Arm Label: Bendamustine + Ofatumumab + Ibrutinib; Type: EXPERIMENTAL; Interventions: Drug: Bendamustine, Drug: Ofatumumab, Drug: Ibrutinib | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Bendamustine + Ofatumumab + Ibrutinib | Intervention Type: DRUG; Name: Ofatumumab; Assigned to Arm(s): Bendamustine + Ofatumumab + Ibrutinib | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Bendamustine + Ofatumumab + Ibrutinib
D: Arm Label: Treatment (alemtuzumab, rituximab, fludarabine phosphate); Type: EXPERIMENTAL; Interventions: Biological: alemtuzumab, Biological: rituximab, Drug: fludarabine phosphate | Intervention Type: BIOLOGICAL; Name: alemtuzumab; Assigned to Arm(s): Treatment (alemtuzumab, rituximab, fludarabine phosphate) | Intervention Type: BIOLOGICAL; Name: rituximab; Assigned to Arm(s): Treatment (alemtuzumab, rituximab, fludarabine phosphate) | Intervention Type: DRUG; Name: fludarabine phosphate; Assigned to Arm(s): Treatment (alemtuzumab, rituximab, fludarabine phosphate)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dietary Energy Restriction and Metabolic Aging in Humans
Brief Summary: This study is one of three CALERIE trials that test the hypothesis that a reduced calorie, nutritionally sound diet increases the length of life and prevents some age-related chronic diseases such as cancer, diabetes, and cardiovascular disease. The three sites that are participating in the CALERIE trial represent a diversity of subject populations and interventional strategies.


Options:
A: Arm Label: A: Study diet; Type: PLACEBO_COMPARATOR; Interventions: Drug: metformin and rosiglitazone | Arm Label: B: Study diet plus Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin and rosiglitazone | Arm Label: C: Study diet plus metformin and avandia; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin and rosiglitazone | Intervention Type: DRUG; Name: metformin and rosiglitazone; Assigned to Arm(s): A: Study diet, B: Study diet plus Metformin, C: Study diet plus metformin and avandia
B: Arm Label: Experimental: Low-Carbohydrate Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Low-Carbohydrate Diet, Behavioral: Mobile App | Arm Label: Experimental: Low-Fat Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Low-Fat Diet, Behavioral: Mobile App | Intervention Type: BEHAVIORAL; Name: Low-Carbohydrate Diet; Assigned to Arm(s): Experimental: Low-Carbohydrate Diet | Intervention Type: BEHAVIORAL; Name: Low-Fat Diet; Assigned to Arm(s): Experimental: Low-Fat Diet | Intervention Type: BEHAVIORAL; Name: Mobile App; Assigned to Arm(s): Experimental: Low-Carbohydrate Diet, Experimental: Low-Fat Diet
C: Intervention Type: BEHAVIORAL; Name: Caloric Restriction (CR); Assigned to Arm(s): N/A
D: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Other: Weight loss intervention | Arm Label: Control Group (delayed intervention); Type: EXPERIMENTAL; Interventions: Other: Weight loss intervention | Intervention Type: OTHER; Name: Weight loss intervention; Assigned to Arm(s): Control Group (delayed intervention), Intervention Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Metabolic Adaptations to Six Month Caloric Restriction
Brief Summary: This study is one of three CALERIE trials that test the hypothesis that a reduced calorie, nutritionally sound diet improves biomarkers of aging and prevents some age-related chronic diseases such as cancer, diabetes, and cardiovascular disease. The three sites that are participating in the CALERIE trial represent a diversity of subject populations and interventional strategies.


Options:
A: Arm Label: Weight Loss Phase; Type: EXPERIMENTAL; Interventions: Behavioral: Weight Loss Phase | Arm Label: Weight Loss Maintenance Phase; Type: EXPERIMENTAL; Interventions: Behavioral: HP-IF, Behavioral: HH | Intervention Type: BEHAVIORAL; Name: Weight Loss Phase; Assigned to Arm(s): Weight Loss Phase | Intervention Type: BEHAVIORAL; Name: HP-IF; Assigned to Arm(s): Weight Loss Maintenance Phase | Intervention Type: BEHAVIORAL; Name: HH; Assigned to Arm(s): Weight Loss Maintenance Phase
B: Arm Label: ketogenic diet and transient fasting; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calorie-restricted ketogenic diet and transient fasting | Arm Label: standard nutrition; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: standard nutrition | Intervention Type: DIETARY_SUPPLEMENT; Name: calorie-restricted ketogenic diet and transient fasting; Assigned to Arm(s): ketogenic diet and transient fasting | Intervention Type: DIETARY_SUPPLEMENT; Name: standard nutrition; Assigned to Arm(s): standard nutrition
C: Intervention Type: BEHAVIORAL; Name: Caloric Restriction (CR); Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): N/A
D: Arm Label: Caloric restriction only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Caloric restriction only | Arm Label: Caloric restriction plus TRF morning; Type: EXPERIMENTAL; Interventions: Behavioral: Caloric restriction plus TRF morning | Arm Label: Caloric restriction plus TRF night; Type: EXPERIMENTAL; Interventions: Behavioral: Caloric restriction plus TRF night | Intervention Type: BEHAVIORAL; Name: Caloric restriction only; Assigned to Arm(s): Caloric restriction only | Intervention Type: BEHAVIORAL; Name: Caloric restriction plus TRF morning; Assigned to Arm(s): Caloric restriction plus TRF morning | Intervention Type: BEHAVIORAL; Name: Caloric restriction plus TRF night; Assigned to Arm(s): Caloric restriction plus TRF night

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial of 17 Alpha-Hydroxyprogesterone Caproate for Prevention of Preterm Birth in Multifetal Gestation (STTARS)
Brief Summary: Women pregnant with twins or triplets are at high risk of preterm birth, yet no intervention or approach has served to reduce this risk. A recently completed trial by the NICHD sponsored Maternal Fetal Medicine Units (MFMU) Network has, for the first time, demonstrated a treatment that substantially reduces the rate of preterm birth in women at high risk for preterm delivery (i.e. progesterone therapy). Preterm birth was reduced by 35% among progesterone-treated women with a singleton pregnancy when compared with women receiving placebo. The current trial compares weekly treatment by injection of progesterone with placebo in women pregnant with twins or triplets.


Options:
A: Intervention Type: DRUG; Name: Micronised progesterone (Utrogestan); Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Progesterone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: 17 alpha-hydroxyprogesterone caproate (17P); Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: 8% progesterone vaginal gel | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Vaginal Gel | Intervention Type: DRUG; Name: 8% progesterone vaginal gel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo Vaginal Gel; Assigned to Arm(s): 2

Answer: C